These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 8953108

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals.
    Hecht DW, Osmolski JR, O'Keefe JP.
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S357-60. PubMed ID: 8324147
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
    Roh KH, Kim S, Kim CK, Yum JH, Kim MS, Yong D, Lee K, Kim JM, Chong Y.
    Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
    [Abstract] [Full Text] [Related]

  • 8. First national survey of antibiotic susceptibility of the Bacteroides fragilis group: emerging resistance to carbapenems in Argentina.
    Fernández-Canigia L, Litterio M, Legaria MC, Castello L, Predari SC, Di Martino A, Rossetti A, Rollet R, Carloni G, Bianchini H, Cejas D, Radice M, Gutkind G, Anaerobe Surveillance Team.
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1309-14. PubMed ID: 22232282
    [Abstract] [Full Text] [Related]

  • 9. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.
    Goldstein EJ, Citron DM.
    J Clin Microbiol; 1988 Nov; 26(11):2361-6. PubMed ID: 3235664
    [Abstract] [Full Text] [Related]

  • 10. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).
    Snydman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJ, Harrell L, Jenkins S, Newton D, Pierson C, Rihs JD, Yu VL, Venezia R, Finegold SM, Rosenblatt JE, Gorbach SL.
    Clin Infect Dis; 2010 Jan 01; 50 Suppl 1():S26-33. PubMed ID: 20067390
    [Abstract] [Full Text] [Related]

  • 11. Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989.
    Cuchural GJ, Snydman DR, McDermott L, Iannini PB, Hill GB, Cleary TJ, O'Keefe JP, Pierson CL, Rihs JD, Finegold SM.
    Clin Ther; 1992 Jan 01; 14(1):122-36. PubMed ID: 1576621
    [Abstract] [Full Text] [Related]

  • 12. Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
    Betriu C, Culebras E, Gómez M, López F, Rodríguez-Avial I, Picazo JJ.
    Antimicrob Agents Chemother; 2008 Jul 01; 52(7):2686-90. PubMed ID: 18474575
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial susceptibility of clinical isolates of Bacteroides fragilis group organisms recovered from 2009 to 2012 in a Korean hospital.
    Yim J, Lee Y, Kim M, Seo YH, Kim WH, Yong D, Jeong SH, Lee K, Chong Y.
    Ann Lab Med; 2015 Jan 01; 35(1):94-8. PubMed ID: 25553287
    [Abstract] [Full Text] [Related]

  • 14. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.
    Aldridge KE, Ashcraft D, Cambre K, Pierson CL, Jenkins SG, Rosenblatt JE.
    Antimicrob Agents Chemother; 2001 Apr 01; 45(4):1238-43. PubMed ID: 11257040
    [Abstract] [Full Text] [Related]

  • 15. Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009.
    Snydman DR, Jacobus NV, McDermott LA, Goldstein EJ, Harrell L, Jenkins SG, Newton D, Patel R, Hecht DW.
    Anaerobe; 2017 Feb 01; 43():21-26. PubMed ID: 27867083
    [Abstract] [Full Text] [Related]

  • 16. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987.
    Cornick NA, Cuchural GJ, Snydman DR, Jacobus NV, Iannini P, Hill G, Cleary T, O'Keefe JP, Pierson C, Finegold SM.
    J Antimicrob Chemother; 1990 Jun 01; 25(6):1011-9. PubMed ID: 2370237
    [Abstract] [Full Text] [Related]

  • 17. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
    Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJ, Finegold SM, Harrell LJ, Hecht DW, Jenkins SG, Pierson C, Venezia R, Yu V, Rihs J, Gorbach SL.
    Antimicrob Agents Chemother; 2007 May 01; 51(5):1649-55. PubMed ID: 17283189
    [Abstract] [Full Text] [Related]

  • 18. Epidemiology and antimicrobial resistance of B. fragilis group organisms isolated from clinical specimen and human intestinal microbiota.
    de Carvalho CB, Moreira JL, Ferreira MC.
    Rev Inst Med Trop Sao Paulo; 1996 May 01; 38(5):329-35. PubMed ID: 9293074
    [Abstract] [Full Text] [Related]

  • 19. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
    Stratton CW, Weeks LS, Aldridge KE.
    Diagn Microbiol Infect Dis; 1992 May 01; 15(4):321-30. PubMed ID: 1611847
    [Abstract] [Full Text] [Related]

  • 20. Epidemiology, antimicrobial susceptibility, pathogenicity, and significance of Bacteroides fragilis group organisms isolated at Los Angeles County-University of Southern California Medical Center.
    Appleman MD, Heseltine PN, Cherubin CE.
    Rev Infect Dis; 1991 May 01; 13(1):12-8. PubMed ID: 2017610
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.